Thermo Fisher Scientific Stock Buy or Sell? TMO Stocks Forecast

Market Capitalization: 213 616 869 000 $
EBITDA: 11 968 000 000 $
Price to Earnings: 31.42
Quarterly Earnings Growth YOY: -0.042
Quarterly Revenue Growth YOY: 0.07
Trailing PE: 31.42
Forward PE: 24.45
Shares Outstanding: 385430000

Thermo Fisher Scientific Stock Buy or Sell? TMO Stocks Analytic Forecasts

March 31, 2023 (22:04)

Thermo Fisher Scientific Inc. (TMO) Sector: Healthcare

We present you the most up-to-date and complete review of analytical trend forecasts and views on the TMO stock market. Experts share their opinions on what to expect from the Thermo Fisher Scientific Inc. stock market. How likely is the stock price to move in a bullish or bearish trend. Which should help you to make the right decision whether to Buy or Sell Thermo Fisher Scientific stocks.

Thermo Fisher Scientific Inc. Stock Market Experts’ Analysis and Forecasting – Sell or Buy TMO Shares?

The most recent analytical view which can help you to answer the worrying question: Should I Buy Stocks Now or Wait? came out under the authorship of Leo Nelissen and is titled

“Thermo Fisher: Dividend Stock Brilliance”

is published on March 30 (2023) and has 7 likes. The review predicts Bullish market trend.

It summarize the following theses:

  • In this article, we discuss Thermo Fisher, a low-yielding, fast-growing dividend stock. Hence, I start with a discussion of why low-yield investing can still add value to your dividend portfolio.
  • Thermo Fisher has a wide-moat business model, strong pricing power, anti-cyclical customers, and strong industry growth, which it is likely to outperform.
  • While the dividend yield is low, dividend growth is high and backed by high safety and a healthy balance sheet.

The author starts his analytic review with the following:

Introduction I’m on thin ice with some readers, as I keep calling some stocks with a yield of less than 1% good dividend stocks.

This author is very popular among the auditory. He has 22428 followers

Leo Nelissen is the contributor of experts community since 2015 and has a great number of published articles – 1894.

One more noteworthy article is written by Waterside Insight under the title

“Thermo Fisher Scientific: From Pandemic Boom To More Sustainable Growth Path”

on March 1 (2023) and has 1 likes. The expert reflects Neutral trend of the market.

Нis theses make you think about whether to add TMO stocks to your investment portfolio or not, and helps to work out your own Thermo Fisher Scientific stock selling strategies:

  • Thermo Fisher’s strong product coverage, especially in life science and pharma research, has propelled its strong growth since the pandemic.
  • The company’s potent top-line growth has enabled it to continually invest in capex and products without impacting its cash flow.
  • Through its expansion, its debt and liabilities stand at a new high, and the management has started making payments toward lowering the burden.
  • Its earnings could have a near-term slowdown but remain robust for the long term.

Waterside Insight starts analysis with such words:

Investment Thesis Thermo Fisher Scientific’s (NYSE:TMO) revenue and margin growth was significantly boosted when the pandemic hit. With boom time, it came with large spending as well. This boost effect will turn into a new robust growth pattern for the company, but it also means it will need to reckon with its high debt and liabilities in the medium term. It’s not an immediate risk, but its earnings could gradually drift lower. The current price is rich for its valuation but not by a significant amount. We recommend a hold.

The author declares an interesting position, and the number of his followers is 178 and it grows, but not that weighty compared to other authors.
Waterside Insight has 30 works published.
The contributor of experts community since 2022. Has published at least 30 articles.

Another analysis presented by Jonathan Weber came out on February 22 (2023). Obviously, coupled with the newer reviews, this forecasting could be useful to find out the best trading strategy for TMO stocks. It sounds like

“Thermo Fisher Scientific: Is This Quality Stock A Buy?”

Article has got 7 likes at the moment and forecasting Neutral trend of the market.

Summarizing the information presented in the review concerning the Thermo Fisher Scientific Inc., the expert says the following:

  • Thermo Fisher Scientific offers solid growth and operates with a recession-resilient business model.
  • TMO stock is well-positioned for further inorganic growth in the future.
  • The valuation is far from low, however.

And here, what comes first:

Article Thesis Thermo Fisher Scientific Inc. (NYSE:TMO) is a high-quality growth stock that has been resilient versus recessions in the past. Fundamentally, the company thus looks attractive, especially in the current environment where a potential recession and rising rates cause uncertainties. On the other hand, shares aren’t cheap, which is why I am not buying into TMO yet.

This author is very popular among the auditory. He has 47690 followers.

Jonathan Weber is the contributor of experts community since 2014 and has at least 1538 analytic reviews published.

The Share Price of Thermo Fisher Scientific Inc. (TMO) for now

What analysts predict: $649.59
52-week high/low: $616.94 / $475.21

50/200 Day Moving Average: $563.62 / $548.96

The average stock price over the previous 50/200 days. For Thermo Fisher Scientific stocks, the 50-day moving average is the resistance level for now. For TMO stocks, the 200-day moving average is the resistance level today.

See the Detailed Predictions for TMO stock with charts and tables

Related Analysis

View all analytics

Buy or Sell ADGI shares?
January 1, 1970

Bright Green Files For U.S. Direct Listing

Buy or Sell BGXX shares? Bright Green Files For U.S. Direct Listing
April 6, 2022
Bright Green Corporation has filed initial information for a direct listing on the Nasdaq Capital Market.

Eli Lilly: Best-Now Near-Term Price Gains Pharmaceuticals Stock

Buy or Sell LLY shares? Eli Lilly: Best-Now Near-Term Price Gains Pharmaceuticals Stock
March 23, 2023
84% of shares held by 3370 “institutional” investors, with over 80% of its $315 Billion market capitalization traded in a year.

If You Like Johnson & Johnson, You’ll Love These Higher-Yielding SWANs

Buy or Sell JNJ shares? If You Like Johnson & Johnson, You’ll Love These Higher-Yielding SWANs
March 10, 2023
Recession is coming and with it plenty of scary headlines about crashing stock prices and financial doom.